{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:14:32Z","timestamp":1790363672458,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejpb.2019.11.009","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T20:10:43Z","timestamp":1575058243000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection"],"prefix":"10.1016","volume":"147","author":[{"given":"Ana","family":"Grenha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana D.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta","family":"Pinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio Jos\u00e9","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Manuela","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2019.11.009_b0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S2213-2600(18)30057-2","article-title":"The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era","volume":"6","author":"Floyd","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejpb.2019.11.009_b0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1166\/jbn.2008.334","article-title":"Inhaled liposomes-current strategies and future challenges","volume":"4","author":"Gaspar","year":"2008","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2019.11.009_b0015","doi-asserted-by":"crossref","DOI":"10.4172\/2161-1068.1000209","article-title":"Current overview of anti-tuberculosis drugs: metabolism and toxicities","volume":"6","author":"Sarkar","year":"2016","journal-title":"Mycobact. Dis."},{"key":"10.1016\/j.ejpb.2019.11.009_b0020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijpharm.2014.12.009","article-title":"Pulmonary drug delivery systems for tuberculosis treatment","volume":"478","author":"Pham","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.11.009_b0025","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.19082\/3005","article-title":"Hematological and liver toxicity of anti-tuberculosis drugs","volume":"8","author":"Mirlohi","year":"2016","journal-title":"Electron. Physician"},{"key":"10.1016\/j.ejpb.2019.11.009_b0030","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1124\/dmd.107.015966","article-title":"A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes","volume":"35","author":"Somers","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2019.11.009_b0035","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2125.2003.01893.x","article-title":"Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2019.11.009_b0040","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/156802608783955629","article-title":"Developments on drug delivery systems for the treatment of mycobacterial infections","volume":"8","author":"Gaspar","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejpb.2019.11.009_b0045","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/molecules21060702","article-title":"Inhalable antitubercular therapy mediated by locust bean gum microparticles","volume":"21","author":"Alves","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2019.11.009_b0050","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.powtec.2018.09.068","article-title":"Spray-drying of konjac glucomannan to produce microparticles for an application as antitubercular drug carriers","volume":"342","author":"Guerreiro","year":"2019","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2019.11.009_b0055","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijpharm.2017.06.088","article-title":"Dual antibiotherapy of tuberculosis mediated by inhalable locust bean gum microparticles","volume":"529","author":"Rodrigues","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.11.009_b0060","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.msec.2018.09.004","article-title":"Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery","volume":"93","author":"Miranda","year":"2018","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ejpb.2019.11.009_b0065","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpb.2015.05.021","article-title":"Pulmonary delivery of pyrazinamide-loaded large porous particles","volume":"94","author":"Pham","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2019.11.009_b0070","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1021\/acs.molpharmaceut.7b00169","article-title":"Microencapsulated solid lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery","volume":"14","author":"Gaspar","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.11.009_b0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/0975-7406.99013","article-title":"Locust bean gum: exploring its potential for biopharmaceutical applications","volume":"4","author":"Grenha","year":"2012","journal-title":"J. Pharm. Bioallied Sci."},{"key":"10.1016\/j.ejpb.2019.11.009_b0080","series-title":"Synthesis and Applications of Copolymers","article-title":"Pharmaceutical polymers","author":"Venkatesan","year":"2014"},{"key":"10.1016\/j.ejpb.2019.11.009_b0085","article-title":"Role of biodegradable polymers in drug delivery","author":"Joshi","year":"2012","journal-title":"Int. J. Curr. Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.11.009_b0090","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3934\/molsci.2016.3.386","article-title":"Approaches in biotechnological applications of natural polymers","volume":"3","author":"Albuquerque","year":"2016","journal-title":"AIMS Mol. Sci."},{"key":"10.1016\/j.ejpb.2019.11.009_b0095","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1590\/S0100-40422011000200023","article-title":"Pharmaceutical use of galactomannans","volume":"34","author":"Silveira","year":"2011","journal-title":"Quim. Nova"},{"key":"10.1016\/j.ejpb.2019.11.009_b0100","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0304-4165(02)00319-7","article-title":"The mannose receptor family","volume":"1572","author":"East","year":"2002","journal-title":"Biochim. Biophys. Acta \u2013 Gen. Subj."},{"key":"10.1016\/j.ejpb.2019.11.009_b0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0168-3659(01)00549-1","article-title":"Targeting to macrophages: role of physicochemical properties of particulate carriers\u2014liposomes and microspheres\u2014on the phagocytosis by macrophages","volume":"79","author":"Ahsan","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2019.11.009_b0110","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.foodhyd.2007.11.004","article-title":"Investigation of molecular weight distribution of LBG galactomannan for flours prepared from individual seeds, mixtures, and commercial samples","volume":"22","author":"Pollard","year":"2008","journal-title":"Food Hydrocoll."},{"key":"10.1016\/j.ejpb.2019.11.009_b0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijantimicag.2007.08.008","article-title":"Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis","volume":"31","author":"Gaspar","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejpb.2019.11.009_b0120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejps.2005.04.009","article-title":"Microencapsulated chitosan nanoparticles for lung protein delivery","volume":"25","author":"Grenha","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.11.009_b0125","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.nano.2015.06.008","article-title":"Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems","volume":"11","author":"Gaspar","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejpb.2019.11.009_b0130","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1128\/AAC.38.10.2346","article-title":"Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis","volume":"38","author":"Jabes","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2019.11.009_b0135","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.2174\/1381612821666150820103910","article-title":"Activation of macrophages: establishing a role for polysaccharides in drug delivery strategies envisaging antibacterial therapy","volume":"21","author":"Rodrigues","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejpb.2019.11.009_b0140","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1080\/01926230701595292","article-title":"Evaluation of organ weights for rodent and non-rodent toxicity studies: a review of regulatory guidelines and a survey of current practices","volume":"35","author":"Michael","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejpb.2019.11.009_b0145","doi-asserted-by":"crossref","first-page":"e70618","DOI":"10.1371\/journal.pone.0070618","article-title":"Acute toxicity of intravenously administered titanium dioxide nanoparticles in mice","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2019.11.009_b0150","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/01926230701595300","article-title":"Society of toxicologic pathology position paper: organ weight recommendations for toxicology studies","volume":"35","author":"Sellers","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejpb.2019.11.009_b0155","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1021\/acs.molpharmaceut.6b00459","article-title":"Inhalable particles for \u201cPincer Therapeutics\u201d targeting nitazoxanide as bactericidal and host-directed agent to macrophages in a mouse model of tuberculosis","volume":"13","author":"Gupta","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.11.009_b0160","doi-asserted-by":"crossref","DOI":"10.1023\/A:1014426530935","article-title":"Fundamental effects of particle morphology on lung delivery: predictions of Stokes\u2019 law and the particular relevance to dry powder inhaler formulation and development","author":"Crowder","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.11.009_b0165","doi-asserted-by":"crossref","DOI":"10.4155\/fmc-2017-0162","article-title":"Antimicrobial molecules in the lung: Formulation challenges and future directions for innovation","author":"Woods","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejpb.2019.11.009_b0170","series-title":"Hayes\u2019 Principles and Methods of Toxicology","first-page":"1117","article-title":"Acute toxicity and eye irritancy","author":"Chan","year":"2014"},{"key":"10.1016\/j.ejpb.2019.11.009_b0175","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1208\/s12249-013-9984-7","article-title":"Evaluation of an abbreviated impactor for fine particle fraction (FPF) determination of metered dose inhalers (MDI)","volume":"14","author":"Guo","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2019.11.009_b0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaerosci.2014.09.003","article-title":"Deposition of particles in the alveolar airways: inhalation and breath-hold with pharmaceutical aerosols","volume":"79","author":"Khajeh-Hosseini-Dalasm","year":"2015","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.ejpb.2019.11.009_b0185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10856-011-4511-4","article-title":"Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb)","volume":"23","author":"Lawlor","year":"2012","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.ejpb.2019.11.009_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.00717","article-title":"Animal models for tuberculosis in translational and precision medicine","volume":"8","author":"Zhan","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejpb.2019.11.009_b0195","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00018-009-0053-z","article-title":"Nanocarriers\u2019 entry into the cell: relevance to drug delivery","volume":"66","author":"Hillaireau","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejpb.2019.11.009_b0200","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/thx.2010.148585","article-title":"Treatment of tuberculosis and optimal dosing schedules","volume":"66","author":"Chang","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.ejpb.2019.11.009_b0205","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1128\/MMBR.00032-13","article-title":"Host-directed therapeutics for tuberculosis: can we harness the host?","volume":"77","author":"Hawn","year":"2013","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.ejpb.2019.11.009_b0210","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1021\/acs.molpharmaceut.5b00016","article-title":"Development and characterization of nanoembedded microparticles for pulmonary delivery of antitubercular drugs against experimental tuberculosis","volume":"12","author":"Goyal","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.11.009_b0215","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejpb.2018.10.020","article-title":"Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2019.11.009_b0220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/hmg\/7.1.75","article-title":"Human beta-mannosidase cDNA characterization and first identification of a mutation associated with human beta-mannosidosis","volume":"7","author":"Alkhayat","year":"1998","journal-title":"Hum Mol Genet."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119313086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119313086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:35:28Z","timestamp":1760546128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641119313086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":44,"alternative-id":["S0939641119313086"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.11.009","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}